A Trial of HTI-1090 in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-01-23
Target enrollment:
Participant gender:
Summary
IDO1 is expressed in a wide variety of human tumors (eg. bladder, breast, colon, DLBCL,
HNSCC, lung, ovarian, uterine, renal…), and contributes to tumoral resistance. HTI-1090 (also
referred as SHR9146 in nonclinical study reports) is an orally bioavailable, highly potent,
novel small-molecule IDO1/TDO dual inhibitor, with favorable preclinical oral bioavailability
and safety profiles.